Inmode Ltd. - (INMD) closed at $13.97 on October 23, 2026, down 0.6% from the previous close, on volume of 395,360 shares (30-day average 442,867).
Data as of October 23, 2026.
23-Oct-2026
Business Wire (Mon, 19-Oct 8:00 AM ET)
PRNewswire (Tue, 13-Oct 7:01 AM ET)
InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool
PRNewswire (Wed, 9-Sep 8:05 AM ET)
PRNewswire (Wed, 5-Aug 7:00 AM ET)
Globe Newswire (Tue, 4-Aug 9:05 AM ET)
Business Wire (Tue, 28-Jul 4:00 PM ET)
Market Chameleon (Thu, 9-Jul 4:57 AM ET)
INMD Receives $16.20 Per Share Buyout Proposal—Special Committee Formed for Independent Review
Market Chameleon (Wed, 24-Jun 7:07 AM ET)
INMD Receives $16.20 Per Share Buyout Proposal—Special Committee Formed for Review
Market Chameleon (Wed, 24-Jun 4:56 AM ET)
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.
Inmode Ltd. - trades on the NASDAQ stock market under the symbol INMD.
As of October 23, 2026, INMD stock price declined to $13.97 with 395,360 million shares trading.
INMD has a beta of 0.45, meaning it tends to be less sensitive to market movements. INMD has a correlation of 0.05 to the broad based SPY ETF.
INMD has a market cap of $803.01 million. This is considered a Small Cap stock.
Last quarter Inmode Ltd. - reported $96 million in Revenue and $.35 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.02.
In the last 3 years, INMD traded as high as $26.80 and as low as $12.72.
The top ETF exchange traded funds that INMD belongs to (by Net Assets): IEFA, SCZ, IXUS, IZRL, AVDV.
INMD has underperformed the market in the last year with a return of -9.8%, while the SPY ETF gained +14.3%. In the last 3 month period, INMD fell short of the market, returning -7.4%, while SPY returned +3.2%. However, in the most recent 2 weeks INMD has outperformed the stock market by returning -1.7%, while SPY returned -2.4%.
INMD support price is $13.95 and resistance is $14.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INMD shares will trade within this expected range on the day.
